Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.verified

INBX

Price:

$15.55

Market Cap:

$225.10M

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothe...[Read more]

Industry

Biotechnology

IPO Date

2024-06-04

Stock Exchange

NASDAQ

Ticker

INBX

The PE Ratio as of November 2024 (TTM) for Inhibrx Biosciences, Inc. (INBX) is 0.13

According to Inhibrx Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 0.13. This represents a change of -103.32% compared to the average of -3.92 of the last 4 quarters.

Inhibrx Biosciences, Inc. (INBX) Historical PE Ratio (quarterly & annually)

How has INBX PE Ratio performed in the past?

The mean historical PE Ratio of Inhibrx Biosciences, Inc. over the last ten years is -24.98. The current 0.13 PE Ratio has changed -152.03% with respect to the historical average. Over the past ten years (40 quarters), INBX's PE Ratio was at its highest in in the June 2024 quarter at 0.03. The PE Ratio was at its lowest in in the March 2019 quarter at -38.60.

Quarterly (TTM)
Annual

Average

-24.98

Median

-16.30

Minimum

-91.20

Maximum

-6.80

Inhibrx Biosciences, Inc. (INBX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Inhibrx Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 84.36%

Maximum Annual PE Ratio = -6.80

Minimum Annual Increase = -66.50%

Minimum Annual PE Ratio = -91.20

Quarterly (TTM)
Annual
YearPE RatioChange
2023-7.429.04%
2022-6.80-66.48%
2021-20.3084.36%
2020-11.01-24.95%
2019-14.67-18.15%
2018-17.93-41.32%
2017-30.55-66.50%

Inhibrx Biosciences, Inc. (INBX) Average PE Ratio

How has INBX PE Ratio performed in the past?

The current PE Ratio of Inhibrx Biosciences, Inc. (INBX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-11.51

5-year avg

-12.04

10-year avg

-24.98

Inhibrx Biosciences, Inc. (INBX) PE Ratio vs. Peers

How is INBX’s PE Ratio compared to its peers?

Inhibrx Biosciences, Inc.’s PE Ratio is greater than Crinetics Pharmaceuticals, Inc. (-17.36), greater than Merus N.V. (-14.30), greater than Lyell Immunopharma, Inc. (-1.54), greater than Kronos Bio, Inc. (-0.56), greater than Opthea Limited (-1.53), greater than Mineralys Therapeutics, Inc. (-5.57), greater than Eliem Therapeutics, Inc. (-2.42), greater than Anebulo Pharmaceuticals, Inc. (-5.95), greater than Merrimack Pharmaceuticals, Inc. (-8.92), greater than Celcuity Inc. (-7.15), greater than Enliven Therapeutics, Inc. (-16.05), greater than Monte Rosa Therapeutics, Inc. (-4.83), greater than Design Therapeutics, Inc. (-5.95), greater than Werewolf Therapeutics, Inc. (-1.83), greater than Ikena Oncology, Inc. (-1.24), greater than Stoke Therapeutics, Inc. (-7.05), less than Protagonist Therapeutics, Inc. (16.87), greater than DICE Therapeutics, Inc. (-23.17), greater than Larimar Therapeutics, Inc. (-7.46), greater than Viridian Therapeutics, Inc. (-6.40),

Build a custom stock screener for Inhibrx Biosciences, Inc. (INBX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibrx Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibrx Biosciences, Inc. (INBX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibrx Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Inhibrx Biosciences, Inc.'s PE Ratio?

How is the PE Ratio calculated for Inhibrx Biosciences, Inc. (INBX)?

What is the highest PE Ratio for Inhibrx Biosciences, Inc. (INBX)?

What is the 3-year average PE Ratio for Inhibrx Biosciences, Inc. (INBX)?

What is the 5-year average PE Ratio for Inhibrx Biosciences, Inc. (INBX)?

How does the current PE Ratio for Inhibrx Biosciences, Inc. (INBX) compare to its historical average?